Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Spread the word! The national map of Lizhu Bio's COVID-19 vaccine inoculation is here
Published Time：
2022-12-21
On December 13, the Joint Prevention and Control Mechanism of the State Council's Leading Group on the Novel Coronavirus Pneumonia Epidemic Prevention and Control issued the "Implementation Plan for the Second Booster Vaccination of COVID-19 Vaccines," and the recombinant novel coronavirus fusion protein (CHO cell) vaccine developed by Livzon Pharma was selected as a preferred combination.
The preferred combinations are:
1. First booster shot (third shot): 2 doses of inactivated vaccine + 1 dose of Livzon Pharma's recombinant novel coronavirus fusion protein (CHO cell) vaccine.
2. Second booster shot (fourth shot): 3 doses of inactivated vaccine + 1 dose of Livzon Pharma's recombinant novel coronavirus fusion protein (CHO cell) vaccine.
The advantages of Livzon Pharma's recombinant novel coronavirus fusion protein (CHO cell) vaccine are prominent:
1. In terms of effectiveness, Livzon Pharma's recombinant novel coronavirus fusion protein vaccine has undergone clinical trials targeting the Omicron variant and is the world's first COVID-19 vaccine to demonstrate effective prevention of Omicron through human clinical trials.
2. In terms of safety, according to clinical results from over 30,000 subjects in 6 countries worldwide, the vaccine has shown good overall safety, with the incidence of adverse reactions such as injection site pain being about 1/10 that of international mRNA vaccines.
Therefore, considering both effectiveness and safety, Livzon Pharma's recombinant novel coronavirus fusion protein vaccine is the preferred choice for the first booster shot (third shot) and the second booster shot (fourth shot). It is also the first booster vaccine reported by CCTV1 News, and a preferred vaccine among many well-known figures.
Clinical trial data show that after sequential boosting, Livzon Pharma's recombinant novel coronavirus fusion protein (CHO cell) vaccine has an absolute protective efficacy (relative to unvaccinated individuals) of 61.35% against Omicron infections with mild or more severe symptoms, which is comparable to the effect of homologous or heterologous third-dose booster mRNA vaccines.
In addition, Livzon Pharma's recombinant novel coronavirus fusion protein (CHO cell) vaccine has a protection rate as high as 71.83% for people with underlying diseases, and a protection rate of 61.19% for people over 60 years old or with underlying diseases, demonstrating its protective advantages for key populations such as those with underlying diseases, the elderly, and high-risk groups.
Get vaccinated and build an immune barrier together. The national vaccination map for Livzon Pharma's recombinant novel coronavirus fusion protein (CHO cell) vaccine is here.
Please " Click here ” to view real-time updated vaccination point information!
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.